# US 11,299,538 B2 · Anti-IGF antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,538 B2
- Document ID: US11299538B2
- Status: Granted
- Kind: B2
- Application number: 16/210,334
- Filed: 2018-12-05
- Published: 2019-07-25
- Granted: 2022-04-12
- Earliest claimed: 2008-12-12
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Paul Adam; Eric Borges; Robert Rauchenberger; Gabriela Wochnik-Veltrup
- Web page: https://patentgrep.com/patent/US11299538B2

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 31/282: Platinum compounds
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 33/243: Platinum; Compounds thereof
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/57595: {involving intracellular compounds}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/475: Assays involving growth factors
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

## Claims

### Claim 1

A DNA molecule encoding the variable heavy chain or the variable light chain of an antibody molecule, wherein said variable heavy chain comprises the amino acid sequence of SEQ ID NO:28 and said variable light chain comprises the amino acid sequence of SEQ ID NO:30.

### Claim 2 (depends on 1)

The DNA molecule of claim 1 which has the nucleotide sequence of SEQ ID NO:27.

### Claim 3 (depends on 1)

The DNA molecule of claim 1 which has the nucleotide sequence of SEQ ID NO:29.

### Claim 4

An expression vector comprising a DNA molecule comprising the nucleotide sequence encoding the variable heavy chain or the variable light chain of an antibody molecule, wherein said variable heavy chain comprises the amino acid sequence of SEQ ID NO:28 and said variable light chain comprises the amino acid sequence of SEQ ID NO:30, wherein said nucleotide sequence is operatively linked to transcriptional and/or translational control sequences.

### Claim 5 (depends on 4)

The expression vector of claim 4 comprising a DNA molecule comprising the nucleotide sequence of SEQ ID NO:27 or SEQ ID NO:29.

### Claim 6 (depends on 4)

The expression vector of claim 4, comprising, in addition, a DNA molecule encoding the constant heavy chain or the constant light chain, respectively, linked to the DNA molecule encoding the variable heavy chain or the variable light chain, respectively, to form a DNA molecule encoding the heavy chain or the light chain of the antibody molecule, respectively.

### Claim 7 (depends on 4)

A host cell comprising two expression vectors of claim 4, wherein the first expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the variable heavy chain of an antibody molecule and the second expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the variable light chain of an antibody molecule.

### Claim 8 (depends on 7)

The host cell of claim 7, which is a mammalian cell.

### Claim 9 (depends on 7)

A method for producing an antibody molecule comprising obtaining a mammalian host cell of claim 7, and cultivating the host cell.

### Claim 10 (depends on 9)

The method according to claim 9, further comprising recovering and purifying the antibody molecule.

### Claim 11 (depends on 4)

A method for producing an antibody molecule, comprising transfecting a mammalian host cell with two expression vectors of claim 4, wherein the first expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the variable heavy chain of an antibody molecule and the second expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the variable light chain of an antibody molecule, cultivating the host cell and recovering and purifying the antibody molecule.

### Claim 12

A DNA molecule encoding the heavy chain or the light chain of an antibody molecule, wherein said heavy chain comprises the amino acid sequence of SEQ ID NO:39 and said light chain comprises the amino acid sequence of SEQ ID NO:40.

### Claim 13

An expression vector comprising a DNA molecule comprising the nucleotide sequence encoding the heavy chain or the light chain of an antibody molecule, wherein said heavy chain comprises the amino acid sequence of SEQ ID NO:39 and said light chain comprises the amino acid sequence of SEQ ID NO:40, wherein said nucleotide sequence is operatively linked to transcriptional and/or translational control sequences.

### Claim 14 (depends on 13)

A host cell comprising two expression vectors of claim 13, wherein the first expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the heavy chain of an antibody molecule and the second expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the light chain of an antibody molecule.

### Claim 15 (depends on 14)

The host cell of claim 14, which is a mammalian cell.

### Claim 16 (depends on 14)

A method for producing an antibody molecule comprising obtaining a mammalian host cell of claim 14, and cultivating the host cell.

### Claim 17 (depends on 16)

The method according to claim 16, further comprising recovering and purifying the antibody molecule.

### Claim 18 (depends on 13)

A method for producing an antibody molecule comprising transfecting a mammalian host cell with two expression vectors of claim 13, wherein the first expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the heavy chain of an antibody molecule and the second expression vector comprises a DNA molecule comprising the nucleotide sequence encoding the light chain of an antibody molecule, cultivating the host cell and recovering and purifying the antibody molecule.